Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
NCT ID: NCT07235527
Last Updated: 2025-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
54 participants
OBSERVATIONAL
2025-11-20
2026-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
NCT02157077
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
NCT02279537
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
NCT03470103
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
NCT02581891
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
NCT02005133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients treated with Yesafili
aflibercept biosimilar used
Aflibercept biosimilar (MY-1701P)
Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aflibercept biosimilar (MY-1701P)
Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
* for whom intravitreal injection has already been clinically indicated
Exclusion Criteria
* History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
* Presence of uveitis
* Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
* Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
* Presence of hereditary retinal dystrophies
* Presence of optic atrophy
45 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saglik Bilimleri Universitesi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sinan KALPAKOĞLU, MD
Ophthalmology Consultant, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prof. Dr. Cemil Taşcıoğlu City Hospital
Istanbul, şişli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
skalpakoglu
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.